NCBIO Blog
Stay up to date with the latest from NCBIO
Recent Posts
Michelle McMurry-Heath, M.D., Ph.D., president and CEO of the Biotechnology Innovation Organization, released the following statement after the House of Representatives passed the Build Back Better Act on Nov. 19: “The legislation that passed the House today will upend a successful Medicare system and weaken the innovation ecosystem that has made America the leader in…
Read MoreDuring a busy week in Congress, Democrats included a change to the Orphan Drug Tax Credit that would negatively impact research on rare diseases affecting millions of Americans. The U.S. House of Representatives has several committees marking up the Senate’s $3.5 trillion budget reconciliation package. (Here’s BIO’s readout, including news on drug price controls and the…
Read MoreThe summer calm is grinding to a halt as members of Congress have returned to D.C. for what is sure to be a busy legislative sprint that could potentially impact all sectors of the biotech industry.
Read MoreIt’s been a while since we’ve talked about what’s going on at the WTO. Here’s the latest news-and why the proposed waiver of vaccine IP is still a bad idea. The status: The World Trade Organization is still considering a proposal backed by India and South Africa (and supported by the U.S.) to waive the…
Read MoreThe PASTEUR Act, legislation designed to make research and development of new antibiotics economically viable, was reintroduced in Congress last week with bipartisan support. Here’s what it would do and why it matters. Antimicrobial resistance is a big problem. AMR occurs when bacteria, viruses, fungi and parasites no longer respond to antibiotics. If we don’t…
Read MoreLegislation like H.R. 3 that fixes prices for prescription medicines would limit patients’ access to new treatments while doing nothing to lower prices at the pharmacy counter.
Read MoreNCBIO is extremely disappointed that the Biden administration has chosen to support waiving critical intellectual property protections for U.S. COVID-19 vaccines. This decision, known as a TRIPS waiver, breaks faith with American innovators, punishes the ingenuity of our life sciences industry and will delay the equitable delivery of COVID vaccines to people around the globe. …
Read MoreBIO President and CEO Dr. Michelle McMurry-Heath sent a letter April 19 to U.S. Trade Representative Ambassador Katherine Tai to explain why the WTO’s proposed “TRIPS waiver” would have global health and economic consequences as the pandemic rages on.
Read MoreA new executive order that slashes Medicare payments to hospitals and physicians for certain medicines will hurt patients’ access to care and financially stress already overburdened hospitals and innovation-based pharmaceutical companies
Read More